TY - JOUR
T1 - Comparison of two methods for carboplatin dosing in children with retinoblastoma
AU - Allen, Steven
AU - Wilson, Matthew W.
AU - Watkins, Amy
AU - Billups, Catherine
AU - Qaddoumi, Ibrahim
AU - Haik, Barrett H.
AU - Rodriguez-Galindo, Carlos
PY - 2010/7/15
Y1 - 2010/7/15
N2 - Background. Carboplatin is the most effective drug in retinoblastoma but systemic clearance is variable in young patients. While most regimens use a flat dose, individualized targeting may provide a more adjusted systemic exposure. Patients and Methods. We compared carboplatin doses between two groups of children with retinoblastoma that were treated using a flat dose of 560 mg/m2 or a targeted AUC of 6.5 using a modified Calvert formula. Results. Ninety-eight patients with retinoblastoma received a total of 576 cycles of carboplatin (median 8 cycles). Fifty patients (51%) received a fixed dose per m2, 32 (33%) received a dose based on AUC, 1 patient received fixed dose per kilogram, and in 15 patients a combination AUC and fixed doses was used. The median cumulative carboplatin dose (mg/m2) for patients who received eight cycles using fixed per m2 dosing was 2151.8 (range, 1414.2-2852.0), compared to 1104.1 for nine patients who received eight cycles using Calvert dosing (range, 779.0-1992.7) (P<0.001). For cycles given using AUC, the median percentage of the hypothetical fixed per m2 dose was 70% (range, 48-134%). Younger patients had larger differences. Patients receiving carboplatin based on fixed per m2 dosing were 3.0 times more likely to have a platelet transfusion (95% confidence interval, 1.3-7.3). Conclusions. Carboplatin administration needs to consider the changes in renal function occurring during the first months of life. The use of a targeted AUC provides the most accurate method; however, mg per kg of body weight dosing is a very reliable alternative method.
AB - Background. Carboplatin is the most effective drug in retinoblastoma but systemic clearance is variable in young patients. While most regimens use a flat dose, individualized targeting may provide a more adjusted systemic exposure. Patients and Methods. We compared carboplatin doses between two groups of children with retinoblastoma that were treated using a flat dose of 560 mg/m2 or a targeted AUC of 6.5 using a modified Calvert formula. Results. Ninety-eight patients with retinoblastoma received a total of 576 cycles of carboplatin (median 8 cycles). Fifty patients (51%) received a fixed dose per m2, 32 (33%) received a dose based on AUC, 1 patient received fixed dose per kilogram, and in 15 patients a combination AUC and fixed doses was used. The median cumulative carboplatin dose (mg/m2) for patients who received eight cycles using fixed per m2 dosing was 2151.8 (range, 1414.2-2852.0), compared to 1104.1 for nine patients who received eight cycles using Calvert dosing (range, 779.0-1992.7) (P<0.001). For cycles given using AUC, the median percentage of the hypothetical fixed per m2 dose was 70% (range, 48-134%). Younger patients had larger differences. Patients receiving carboplatin based on fixed per m2 dosing were 3.0 times more likely to have a platelet transfusion (95% confidence interval, 1.3-7.3). Conclusions. Carboplatin administration needs to consider the changes in renal function occurring during the first months of life. The use of a targeted AUC provides the most accurate method; however, mg per kg of body weight dosing is a very reliable alternative method.
KW - Carboplatin
KW - Glomerular filtration rate
KW - Retinoblastoma
UR - http://www.scopus.com/inward/record.url?scp=77953269029&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953269029&partnerID=8YFLogxK
U2 - 10.1002/pbc.22467
DO - 10.1002/pbc.22467
M3 - Article
C2 - 20486170
AN - SCOPUS:77953269029
SN - 1545-5009
VL - 55
SP - 47
EP - 54
JO - Pediatric Blood and Cancer
JF - Pediatric Blood and Cancer
IS - 1
ER -